A Critical Review on Analytical Methods for FDA Approved Drugs: Olaparib

Olaparib treats Breast Cancer susceptibility protein (BRCA)‐associated, platinum‐sensitive ovarian cancer. Olaparib is a poly(ADP‐ribose) polymerase inhibitor , thereby blocking the repair of single‐strand DNA breaks. This results in synthetic lethality in BRCA‐associated cancer cells, which have a dysfunction of another DNA repair pathway – homologous recombination. As per literature, Olaparib was first approved by Food and drug administration (FDA) and EU in December 2014 and by Health Canada in April 2016. Therefore, the main objective of this analysis of Olaparib in pharmaceutical and biological formulation is in both qualitative and quantitative terms. In this review article, we have summarized UV/Vis spectroscopy, high-performance liquid chromatography (HPLC), High-performance thin-layer chromatography (HPTLC), Ultra-performance liquid chromatography (UPLC), Liquid chromatography-mass spectroscopy-mass spectroscopy (LC-MS/MS) etc. based methods for estimation of Olaparib. In addition to that, we have discussed the bioanalytical methods for Olaparib analysis. In conclusion, this review article will help to research scholars for further method development for drug estimation in pharmaceutical dosage forms and biological fluids.